Alfuzosin information

Alfuzosin
Clinical data
Pronunciation	/ælˈfjuːzoʊsɪn/ al-FEW-zoh-sin
Trade names	Uroxatral, others
AHFS/Drugs.com	Monograph
MedlinePlus	a64002
License data	US DailyMed: Alfuzosin;
Pregnancy; category	AU: B2; ;
Routes of; administration	By mouth
ATC code	G04CA01 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	49%
Protein binding	82–90%
Metabolism	Liver (CYP3A4-mediated)
Elimination half-life	10 hours
Excretion	Feces (69%) and Urine (24%)
Identifiers
	IUPAC name (RS)-N-[3-[(4-Amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide;
CAS Number	81403-80-7 ;
PubChem CID	2092;
IUPHAR/BPS	7109;
DrugBank	DB00346 ;
ChemSpider	2008 ;
UNII	90347YTW5F;
KEGG	D07124 ;
ChEBI	CHEBI:51141 ;
ChEMBL	ChEMBL709 ;
CompTox Dashboard (EPA)	DTXSID6048549 ;
ECHA InfoCard	100.108.671
Chemical and physical data
Formula	C19H27N5O4
Molar mass	389.456 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NCCCN(c2nc1cc(OC)c(OC)cc1c(n2)N)C)C3OCCC3;
	InChI InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23) ; Key:WNMJYKCGWZFFKR-UHFFFAOYSA-N ;
	(verify)

Alfuzosin, sold under the brand name Uroxatral among others, is a medication of the α₁ blocker class. It is used to treat benign prostatic hyperplasia (BPH).^[1]

As an antagonist of the α₁ adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making urination easier.

Alfuzosin was patented in 1978 and approved for medical use in 1988.^[2] It was approved in the US for benign prostatic hyperplasia in 2003. In 2020, it was the 336th-most commonly prescribed medication in the United States, with more than 700 thousand prescriptions.^[3]^[4]

^ Lepor H (August 2016). "Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia". The Urologic Clinics of North America. 43 (3): 311–23. doi:10.1016/j.ucl.2016.04.009. PMC 2213889. PMID 27476124.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 455. ISBN 9783527607495.
^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
^ "Alfuzosin - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.

[1] Lepor H (August 2016). "Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia". The Urologic Clinics of North America. 43 (3): 311–23. doi:10.1016/j.ucl.2016.04.009. PMC 2213889. PMID 27476124.

[2] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 455. ISBN 9783527607495.

[3] "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.

[4] "Alfuzosin - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.

Alfuzosin information

and 28 Related for: Alfuzosin information

Alfuzosin

Alpha blocker

ATC code G04

Rilmenidine

Benign prostatic hyperplasia

Risperidone

Buspirone

Adrenaline

Beta blocker

Quetiapine

Aripiprazole

Phenylephrine

Salbutamol

Dutasteride

Promethazine

LSD

Chlorpromazine

Cyclobenzaprine

Trazodone

Olanzapine

Mirabegron

Clonidine

Prochlorperazine

Tizanidine

Unichem Laboratories

Propranolol

Tyrosine

Clozapine

Clinical data

Pronunciation	/ælˈfjuːzoʊsɪn/ al-FEW-zoh-sin
Trade names	Uroxatral, others
AHFS/Drugs.com	Monograph
MedlinePlus	a64002
License data	US DailyMed: Alfuzosin
Pregnancy category	AU: B2
Routes of administration	By mouth
ATC code	G04CA01 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	49%
Protein binding	82–90%
Metabolism	Liver (CYP3A4-mediated)
Elimination half-life	10 hours
Excretion	Feces (69%) and Urine (24%)
Identifiers
IUPAC name (RS)-N-[3-[(4-Amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
CAS Number	81403-80-7^Y
PubChem CID	2092
IUPHAR/BPS	7109
DrugBank	DB00346^Y
ChemSpider	2008^Y
UNII	90347YTW5F
KEGG	D07124^Y
ChEBI	CHEBI:51141^Y
ChEMBL	ChEMBL709^Y
CompTox Dashboard (EPA)	DTXSID6048549
ECHA InfoCard	100.108.671
Chemical and physical data
Formula	C₁₉H₂₇N₅O₄
Molar mass	389.456 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C(NCCCN(c2nc1cc(OC)c(OC)cc1c(n2)N)C)C3OCCC3
InChI InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)^Y Key:WNMJYKCGWZFFKR-UHFFFAOYSA-N^Y
(verify)